COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
复制标题
DOI：
10.1177/13524585211003476
复制
发表时间：
2021-05
期刊：
影响因子：
--
通讯作者：
Gurevich M
中科院分区：
文献类型：
--
作者：
Achiron A;Dolev M;Menascu S;Zohar DN;Dreyer-Alster S;Miron S;Shirbint E;Magalashvili D;Flechter S;Givon U;Guber D;Stern Y;Polliack M;Falb R;Gurevich M
自2019冠状病毒病（COVID-19）疫苗接种可用以来，需要仔细评估与多发性硬化症（MS）患者接种疫苗相关的风险。在大型MS患者队列中描述COVID-19疫苗接种后的安全性和立即复发的发生率。我们评估了BNT 162 b2 COVID-19疫苗接种在成年MS患者中的安全性。2020年12月20日至2021年1月25日期间，555名多发性硬化症患者接种了第一剂BNT 162 b2疫苗，435名患者接种了第二剂。在首次接种后，有三例COVID-19感染病例。COVID-19疫苗的安全性特征是注射部位疼痛、疲劳和头痛。在第一次和第二次疫苗接种后的中位随访时间分别为20天和38天，未观察到复发活动的风险增加。在第一次和第二次接种后，急性复发患者的比率分别为2.1%和1.6%，与同期未接种疫苗患者的比率相似。在年轻患者（18-55岁）、低残疾患者（扩展残疾状态量表（EDSS）3.0）和接受免疫调节药物治疗的患者中，不良事件发生率略有增加。COVID-19 BNT 162 b2疫苗被证明对MS患者是安全的。没有注意到复发活动的风险增加。
Since vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed. Characterize safety and occurrence of immediate relapses following COVID-19 vaccination in a large cohort of MS patients. We assessed the safety of BNT162b2 COVID-19 vaccination in adult MS patients. Between 20 December 2020 and 25 January 2021, 555 MS patients received the first dose of BNT162b2 vaccine and 435 received the second dose. There were three cases of COVID-19 infection encountered after the first dose. Safety profile of COVID-19 vaccine was characterized by pain at the injection site, fatigue, and headache. No increased risk of relapse activity was noted over a median follow-up of 20 and 38 days after first and second vaccine doses, respectively. The rate of patients with acute relapse was 2.1% and 1.6% following the first and second doses, respectively, similar to the rate in non-vaccinating patients during the corresponding period. Mild increase in the rate of adverse events was noted in younger patients (18–55 years), among patients with lower disability (Expanded Disability Status Scale (EDSS) ⩽3.0), and in patients treated with immunomodulatory drugs. COVID-19 BNT162b2 vaccine proved safe for MS patients. No increased risk of relapse activity was noted.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
12.8
作者：
Chen, RT;Pless, R;DeStefano, F
通讯作者：
DeStefano, F
影响因子：
5.8
作者：
Oikonen, Mervi;Laaksonen, Mikko;Salmi, Aimo
通讯作者：
Salmi, Aimo
影响因子：
--
作者：
Farez, Mauricio F.;Correale, Jorge
通讯作者：
Correale, Jorge
影响因子：
9.9
作者：
Bar-Or, Amit;Calkwood, Jonathan C.;Traboulsee, Anthony
通讯作者：
Traboulsee, Anthony